First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.
Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.
